Helixgate

Helixgate

Uncategorized

This week in Drug Discovery (20 – 24 April) 

Published

on

News round-up for 20 – 24 April by Bruno Quinney, Content Team at DDW. 

This week, an obesity drug could improve liver health independent of weight loss. Elsewhere, Lilly is back in the news for both its type 2 diabetes drug and the company’s latest acquisition. 

The top stories: 

 

GLP-1 improves liver health independent of weight loss

 

Researchers at Sinai Health have found that semaglutide acts directly on a subset of liver cells to improve organ function and does so independently of weight loss.   

Read more… 

Digital lung ‘twins’ could predict drug efficacy in humans 


Healthcare company Ebenbuild has developed lung digital twin technology, which uses patient-specific models to predict drug deposition.  

Read more… 

 

MHRA grants trial authorisation to CRS therapy 


The TOPICAL trial will investigate Poolbeg Pharma’s therapy, POLB 001, in approximately 30 relapsed/refractory multiple myeloma patients receiving the approved bispecific antibody teclistamab.  

Read more… 

 

 

Lilly publishes data confirming Foundayo’s safety profile  


Eli Lilly has shared positive topline results from the Phase III ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron), compared to insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk.  

Read more… 

 

 

Antibody-drug conjugate company CrossBridge Bio acquired by Lilly 


Eli Lilly has signed a definitive agreement to acquire preclinical biotechnology company CrossBridge Bio for up to $300 million in cash, inclusive of an upfront payment and a subsequent milestone-dependent payment.  

Read more… 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The post This week in Drug Discovery (20 – 24 April)  appeared first on Drug Discovery World (DDW).

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Experts wonder ‘Where is the CDC?’ as hantavirus outbreak unfolds

Published

on

NEW YORK — No quick dispatching of disease investigators. No televised news conference to inform the public. No timely health alerts to doctors.

In the midst of a hantavirus outbreak that involves Americans and is making headlines around the world, the U.S. government’s top public health agency, the Centers for Disease Control and Prevention, has been uncharacteristically missing in action, according to a number of experts.

Read the rest…

Continue Reading

Uncategorized

Opinion: Dr. Glaucomflecken wants the corporatization of medicine to be national news

Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Will Flanary, aka Dr. Glaucomflecken. Be sure to sign up for the weekly “First Opinion Podcast” on Apple PodcastsSpotify, or wherever you get your podcasts. Get alerts about each new episode by signing up for the “First Opinion Podcast” newsletter. And don’t forget to sign up for the First Opinion newsletter, delivered every Sunday.

Torie Bosch: Will Flanary is better known as Dr. Glaucomflecken. He is social media’s most famous comedian slash doctor, and he’s not afraid of punching up.

Read the rest…

Read More

Published

on

Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Will Flanary, aka Dr. Glaucomflecken. Be sure to sign up for the weekly “First Opinion Podcast” on Apple PodcastsSpotify, or wherever you get your podcasts. Get alerts about each new episode by signing up for the “First Opinion Podcast” newsletter. And don’t forget to sign up for the First Opinion newsletter, delivered every Sunday.

Torie Bosch: Will Flanary is better known as Dr. Glaucomflecken. He is social media’s most famous comedian slash doctor, and he’s not afraid of punching up.

Read the rest…

Read More

Continue Reading

Uncategorized

Biotech’s new company model; The super poop behind a startup launch; and more

Biotech’s new company model; The super poop behind a startup launch; and more

Published

on

Welcome back to another edition of Endpoints Weekly! Earnings season is in full swing, but we had plenty of original reporting and exclusives you won’t find anywhere else this week. Chief among them: Andrew Dunn’s …​ ​Read More

Continue Reading
Advertisement

Trending